Clinical audit of estradiol implant therapy: Long duration of action and implications in non-hysterectomised women

•Estrapel is an oestradiol implant that provides a non-oral treatment option for menopausal hormone therapy.•Its prolonged action makes patient selection important, as the implants cannot easily be removed.•In women with an intact uterus, the continuation of progestin therapy after cessation of impl...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Maturitas Ročník 94; s. 84 - 86
Hlavní autori:	Wheatley, Shaday, Bell, Robin J., Stuckey, Bronwyn G.A., Robinson, Penelope J., Davis, Susan R.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Ireland Elsevier B.V 01.12.2016
Predmet:	Clinical Audit Drug Implants Estradiol - administration & dosage Estradiol - therapeutic use Estrogen Replacement Therapy - methods Female Hormone implant Humans Internal Medicine Menopausal hormone therapy Middle Aged Obstetrics and Gynecology Oestradiol Postmenopause Retrospective Studies Time Factors Oestradiol Hormone implant Menopausal hormone therapy
ISSN:	0378-5122, 1873-4111, 1873-4111
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	•Estrapel is an oestradiol implant that provides a non-oral treatment option for menopausal hormone therapy.•Its prolonged action makes patient selection important, as the implants cannot easily be removed.•In women with an intact uterus, the continuation of progestin therapy after cessation of implant therapy is imperative. We audited the files of 114 postmenopausal women who had been treated with subcutaneous Estrapel (50mg oestradiol implants). Of the 92 women who received more than one implant, the median number of days between implants was 223.5 (range 49–875), with an estimated median time to return to baseline of 311days (range 108–1228). Although oestradiol implants can provide an excellent non-oral treatment option, their prolonged action makes patient selection important, as the implants cannot easily be removed. In women with an intact uterus, the continuation of progestin therapy after cessation of implant therapy is imperative.
AbstractList	We audited the files of 114 postmenopausal women who had been treated with subcutaneous Estrapel (50mg oestradiol implants). Of the 92 women who received more than one implant, the median number of days between implants was 223.5 (range 49-875), with an estimated median time to return to baseline of 311days (range 108-1228). Although oestradiol implants can provide an excellent non-oral treatment option, their prolonged action makes patient selection important, as the implants cannot easily be removed. In women with an intact uterus, the continuation of progestin therapy after cessation of implant therapy is imperative.We audited the files of 114 postmenopausal women who had been treated with subcutaneous Estrapel (50mg oestradiol implants). Of the 92 women who received more than one implant, the median number of days between implants was 223.5 (range 49-875), with an estimated median time to return to baseline of 311days (range 108-1228). Although oestradiol implants can provide an excellent non-oral treatment option, their prolonged action makes patient selection important, as the implants cannot easily be removed. In women with an intact uterus, the continuation of progestin therapy after cessation of implant therapy is imperative. •Estrapel is an oestradiol implant that provides a non-oral treatment option for menopausal hormone therapy.•Its prolonged action makes patient selection important, as the implants cannot easily be removed.•In women with an intact uterus, the continuation of progestin therapy after cessation of implant therapy is imperative. We audited the files of 114 postmenopausal women who had been treated with subcutaneous Estrapel (50mg oestradiol implants). Of the 92 women who received more than one implant, the median number of days between implants was 223.5 (range 49–875), with an estimated median time to return to baseline of 311days (range 108–1228). Although oestradiol implants can provide an excellent non-oral treatment option, their prolonged action makes patient selection important, as the implants cannot easily be removed. In women with an intact uterus, the continuation of progestin therapy after cessation of implant therapy is imperative. Highlights • Estrapel is an oestradiol implant that provides a non-oral treatment option for menopausal hormone therapy. • Its prolonged action makes patient selection important, as the implants cannot easily be removed. • In women with an intact uterus, the continuation of progestin therapy after cessation of implant therapy is imperative. We audited the files of 114 postmenopausal women who had been treated with subcutaneous Estrapel (50mg oestradiol implants). Of the 92 women who received more than one implant, the median number of days between implants was 223.5 (range 49-875), with an estimated median time to return to baseline of 311days (range 108-1228). Although oestradiol implants can provide an excellent non-oral treatment option, their prolonged action makes patient selection important, as the implants cannot easily be removed. In women with an intact uterus, the continuation of progestin therapy after cessation of implant therapy is imperative.
Author	Wheatley, Shaday Bell, Robin J. Stuckey, Bronwyn G.A. Davis, Susan R. Robinson, Penelope J.
Author_xml	– sequence: 1 givenname: Shaday surname: Wheatley fullname: Wheatley, Shaday organization: The Women’s Health Research Program, School of Public Health and Preventive Medicine, Monash University, Level 6 The Alfred Centre, 99 Commercial Road, Melbourne,Victoria, 3004, Australia – sequence: 2 givenname: Robin J. surname: Bell fullname: Bell, Robin J. organization: The Women’s Health Research Program, School of Public Health and Preventive Medicine, Monash University, Level 6 The Alfred Centre, 99 Commercial Road, Melbourne,Victoria, 3004, Australia – sequence: 3 givenname: Bronwyn G.A. surname: Stuckey fullname: Stuckey, Bronwyn G.A. organization: Keogh Institute for Medical Research, Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, School of Medicine and Pharmacology, University of Western Australia, Nedlands WA 6009, Australia – sequence: 4 givenname: Penelope J. surname: Robinson fullname: Robinson, Penelope J. organization: The Women’s Health Research Program, School of Public Health and Preventive Medicine, Monash University, Level 6 The Alfred Centre, 99 Commercial Road, Melbourne,Victoria, 3004, Australia – sequence: 5 givenname: Susan R. orcidid: 0000-0002-2955-0415 surname: Davis fullname: Davis, Susan R. email: susan.davis@monash.edu organization: The Women’s Health Research Program, School of Public Health and Preventive Medicine, Monash University, Level 6 The Alfred Centre, 99 Commercial Road, Melbourne,Victoria, 3004, Australia
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/27823750$$D View this record in MEDLINE/PubMed
BookMark	eNqNkktvEzEUhS1URNPCXwAv2UzwY2ZsIwGqohaQIrEA1pbjuaYOM3awZ0D593iS0EUlpKz80HeP7j3nXqGLEAMg9IqSJSW0fbNdDmackh9NXrLysSRqSYh8ghZUCl7VlNILtCBcyKqhjF2iq5y3hJCG8PoZumRCMi4askBp1fvgremxmTo_4ugw5DGZzsce-2HXmzDi8R6S2e3f4nUMP3A3JTP6GGbW2MPNhO4AF6H5nbEPuHRc3e_zCAnsGAefocN_4gDhOXrqTJ_hxem8Rt_vbr-tPlXrLx8_r27Wla0lG6vWOQl1ozaibTdOtVxy65Qxbc1421gilRMbUtcKWlJTIRvLpWsUc1Aryznwa_T6qLtL8ddUptKlCQt9GQnilDWVXDApFRMFfXlCp80And4lP5i01_98KoA4AjbFnBO4B4QSPSeit_ohET0noonSJZFS-e5RpS3M7FJx2fdn1N8c66FY9dtD0tl6CBY6Pxuru-jP0Hj_SMOeUv8Je8jbOKVQktBUZ6aJ_jrvzbw2tOWEscP4H_4vcFYLfwGlrtlZ
CitedBy_id	crossref_primary_10_1097_PPO_0000000000000597 crossref_primary_10_3389_frph_2024_1378644 crossref_primary_10_1071_SH23126 crossref_primary_10_1038_s41574_022_00685_4 crossref_primary_10_1097_AOG_0000000000005989 crossref_primary_10_1097_GME_0000000000001813
Cites_doi	10.1111/j.1479-828X.1998.tb03112.x 10.1016/0378-5122(84)90008-2 10.1136/bmj.294.6577.936 10.1016/0378-5122(94)00898-H 10.1111/j.1365-2265.1995.tb02660.x
ContentType	Journal Article
Copyright	2016 Elsevier Ireland Ltd Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
Copyright_xml	– notice: 2016 Elsevier Ireland Ltd – notice: Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1016/j.maturitas.2016.09.008
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1873-4111
EndPage	86
ExternalDocumentID	27823750 10_1016_j_maturitas_2016_09_008 S0378512216302250 1_s2_0_S0378512216302250
Genre	Journal Article
GroupedDBID	--- --K --M -~X .1- .FO .GJ .~1 0R~ 1B1 1P~ 1~. 1~5 29M 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABGSF ABIVO ABJNI ABLJU ABMAC ABMZM ABUDA ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACLOT ACRLP ACVFH ADBBV ADCNI ADEZE ADUVX AEBSH AEFWE AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGRDE AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEC HMK HMO HVGLF HZ~ IHE J1W KOM LPU M27 M2X M41 MO0 N9A O-L O9- OAUVE OQ. OZT P-8 P-9 P2P PC. PH~ Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSU SSZ T5K UNMZH WUQ Z5R ZGI ~G- ~HD 1RT AACTN AFCTW AFKWA AJOXV AMFUW RIG AAIAV ABLVK ABYKQ AJBFU DOVZS LCYCR 9DU AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8
ID	FETCH-LOGICAL-c482t-6ff8e459b766bf96383cf9aa642365c089f7b0449e6041785c38f592fe49c33e3
ISICitedReferencesCount	6
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000388153800014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0378-5122 1873-4111
IngestDate	Sat Sep 27 17:51:00 EDT 2025 Wed Feb 19 02:17:29 EST 2025 Sat Nov 29 07:13:29 EST 2025 Tue Nov 18 20:53:53 EST 2025 Fri Feb 23 02:29:48 EST 2024 Tue Feb 25 19:59:36 EST 2025 Tue Oct 14 19:36:33 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Keywords	Oestradiol Hormone implant Menopausal hormone therapy
Language	English
License	Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c482t-6ff8e459b766bf96383cf9aa642365c089f7b0449e6041785c38f592fe49c33e3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ORCID	0000-0002-2955-0415
PMID	27823750
PQID	1837288927
PQPubID	23479
PageCount	3
ParticipantIDs	proquest_miscellaneous_1837288927 pubmed_primary_27823750 crossref_primary_10_1016_j_maturitas_2016_09_008 crossref_citationtrail_10_1016_j_maturitas_2016_09_008 elsevier_sciencedirect_doi_10_1016_j_maturitas_2016_09_008 elsevier_clinicalkeyesjournals_1_s2_0_S0378512216302250 elsevier_clinicalkey_doi_10_1016_j_maturitas_2016_09_008
PublicationCentury	2000
PublicationDate	2016-12-01
PublicationDateYYYYMMDD	2016-12-01
PublicationDate_xml	– month: 12 year: 2016 text: 2016-12-01 day: 01
PublicationDecade	2010
PublicationPlace	Ireland
PublicationPlace_xml	– name: Ireland
PublicationTitle	Maturitas
PublicationTitleAlternate	Maturitas
PublicationYear	2016
Publisher	Elsevier B.V
Publisher_xml	– name: Elsevier B.V
References	Templeman, Quinn, Hansen, Moreton, Baber (bib0025) 1998; 38 Davis, McCloud, Strauss, Burger (bib0015) 1995; 21 Burger, Hailes, Menelaus (bib0005) 1984; 6 Buckler, Kalsi, Cantrill, Anderson (bib0020) 1995; 42 Burger, Hailes, Nelson, Menelaus (bib0010) 1987; 294 Burger (10.1016/j.maturitas.2016.09.008_bib0005) 1984; 6 Buckler (10.1016/j.maturitas.2016.09.008_bib0020) 1995; 42 Davis (10.1016/j.maturitas.2016.09.008_bib0015) 1995; 21 Burger (10.1016/j.maturitas.2016.09.008_bib0010) 1987; 294 Templeman (10.1016/j.maturitas.2016.09.008_bib0025) 1998; 38
References_xml	– volume: 21 start-page: 227 year: 1995 end-page: 236 ident: bib0015 article-title: Testosterone enhances estradiol’s effects on postmenopausal bone density and sexuality publication-title: Maturitas – volume: 42 start-page: 445 year: 1995 end-page: 450 ident: bib0020 article-title: An audit of oestradiol levels and implant frequency in women undergoing subcutaneous implant therapy publication-title: Clin. Endocrinol. (Oxf) – volume: 6 start-page: 351 year: 1984 ident: bib0005 article-title: The management of persistent symptoms with estradiol-testosterone implants: clinical, lipid and hormonal results publication-title: Maturitas – volume: 38 start-page: 455 year: 1998 end-page: 460 ident: bib0025 article-title: An audit of oestrogen implant hormone replacement therapy publication-title: Aust. N. Z. J. Obstet. Gynaecol. – volume: 294 start-page: 936 year: 1987 end-page: 937 ident: bib0010 article-title: Effect of combined implants of estradiol and testosterone on libido in postmenopausal women publication-title: Br. Med. J. – volume: 38 start-page: 455 issue: 4 year: 1998 ident: 10.1016/j.maturitas.2016.09.008_bib0025 article-title: An audit of oestrogen implant hormone replacement therapy publication-title: Aust. N. Z. J. Obstet. Gynaecol. doi: 10.1111/j.1479-828X.1998.tb03112.x – volume: 6 start-page: 351 year: 1984 ident: 10.1016/j.maturitas.2016.09.008_bib0005 article-title: The management of persistent symptoms with estradiol-testosterone implants: clinical, lipid and hormonal results publication-title: Maturitas doi: 10.1016/0378-5122(84)90008-2 – volume: 294 start-page: 936 year: 1987 ident: 10.1016/j.maturitas.2016.09.008_bib0010 article-title: Effect of combined implants of estradiol and testosterone on libido in postmenopausal women publication-title: Br. Med. J. doi: 10.1136/bmj.294.6577.936 – volume: 21 start-page: 227 year: 1995 ident: 10.1016/j.maturitas.2016.09.008_bib0015 article-title: Testosterone enhances estradiol’s effects on postmenopausal bone density and sexuality publication-title: Maturitas doi: 10.1016/0378-5122(94)00898-H – volume: 42 start-page: 445 issue: 5 year: 1995 ident: 10.1016/j.maturitas.2016.09.008_bib0020 article-title: An audit of oestradiol levels and implant frequency in women undergoing subcutaneous implant therapy publication-title: Clin. Endocrinol. (Oxf) doi: 10.1111/j.1365-2265.1995.tb02660.x
SSID	ssj0005034
Score	2.185135
Snippet	•Estrapel is an oestradiol implant that provides a non-oral treatment option for menopausal hormone therapy.•Its prolonged action makes patient selection... Highlights • Estrapel is an oestradiol implant that provides a non-oral treatment option for menopausal hormone therapy. • Its prolonged action makes patient... We audited the files of 114 postmenopausal women who had been treated with subcutaneous Estrapel (50mg oestradiol implants). Of the 92 women who received more...
SourceID	proquest pubmed crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	84
SubjectTerms	Clinical Audit Drug Implants Estradiol - administration & dosage Estradiol - therapeutic use Estrogen Replacement Therapy - methods Female Hormone implant Humans Internal Medicine Menopausal hormone therapy Middle Aged Obstetrics and Gynecology Oestradiol Postmenopause Retrospective Studies Time Factors
Title	Clinical audit of estradiol implant therapy: Long duration of action and implications in non-hysterectomised women
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S0378512216302250 https://www.clinicalkey.es/playcontent/1-s2.0-S0378512216302250 https://dx.doi.org/10.1016/j.maturitas.2016.09.008 https://www.ncbi.nlm.nih.gov/pubmed/27823750 https://www.proquest.com/docview/1837288927
Volume	94
WOSCitedRecordID	wos000388153800014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1873-4111 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0005034 issn: 0378-5122 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9swFBZpOsZexq5ddika7K24-C6pb0mWLutoCWsHeRO2ItOUzC65dN2v3l_YOZbsul1Ku8FeTGJ8JKHzSTrn6FwI-SCUx5MQtBMmlHZCzw0coXXiRDpNXSWScCJMsQl2dMTHYzFqtX5VsTAXM5bn_PJSnP9XVsM7YDaGzv4Fu-tG4QX8BqbDE9gOz3sxvl_FOiYYcIHCoEZzxmRazDAmcgZTuWOirspkTzMsNjRZzWvRsSoejpcKN9zN8yJ3TjH1M26TBSAEfdcxhUNTxD3EVKHTZbK4tt9b0_jxaTJJTG1rvCPCraU2CNgbkDIibeegtNT2esfG6vOx_DsalrJ2d380bJRBRs8Q0-S8yH_8zHc-dZvE-1-7_TqIrRnuNoJtflaca9NXr1cmIsARodQ9LFDBEGVDWLATA6-aFhIvbnib2MgwwCIINv7aI8NYL852v1ezg_5-cZn81uVXp2TlGTDof_Gchb_rOsfYLjYLIi1IQiZ_7o3k3Z5c-NKVf3y6QTZ9FgneJpvdz4PxwZVXkhuYjGd2yNdcEtcO8TaB6jaFqRScTp6Qx1bjoV2D1KekpfNn5OGh9el4TuYVYGkJWFpktAYstYClFrB7FOFKK7jitwauFOBKm3Cl05yugSst4fqCfNsfnPSHjq0E4qiQ-0snzjKuw0ikLI7TDM-MQGUiSUB5DuJIuVxkLHXDUOjYDT2YahXwLBJ-pkOhgkAHL0kb-tSvCPWU8iI2SUSaqjDzeRrEOmBplCagPKdR1CFxNZ1S2TT5WK1lJit_yDNZ80EiH6QrJPChQ9ya8NxkirmbhFf8klUgNKwYCdC8m5StI9ULuxMt5G3Q65C9mtJK2UZ6vl-37ytYSWAbXi4muS5W0B0PmM-58FmHbBm81dPgM0yJFbmv_3nQb8ijq5X9lrSX85V-Rx6oi-V0Md8mG2zMt-1S-g0XqwsH
linkProvider	Elsevier
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+audit+of+estradiol+implant+therapy%3A+long+duration+of+action+and+implications+in+non-hysterectomised+women&rft.jtitle=Maturitas&rft.au=Wheatley%2C+Shaday%2C+B+Med+Sci&rft.au=Bell%2C+Robin+J%2C+MBBS%2C+PhD%2C+MPH%2C+FAFPHM&rft.au=Stuckey%2C+Bronwyn+GA%2C+MBBS%2C+FRACP&rft.au=Robinson%2C+Penelope+J%2C+BBiomed+Sci+%28Hons%29%2C+M+Biostat&rft.date=2016-12-01&rft.issn=0378-5122&rft_id=info:doi/10.1016%2Fj.maturitas.2016.09.008&rft.externalDBID=ECK1-s2.0-S0378512216302250&rft.externalDocID=1_s2_0_S0378512216302250
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0378-5122&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0378-5122&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0378-5122&client=summon